• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[眼前部的药代动力学]

[Pharmacokinetics of the anterior eye].

作者信息

Bell K, Pfeiffer N, Grus F H

机构信息

Augenklinik, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland,

出版信息

Ophthalmologe. 2014 Feb;111(2):107-12. doi: 10.1007/s00347-013-2931-x.

DOI:10.1007/s00347-013-2931-x
PMID:24337342
Abstract

The pharmacokinetics of the anterior eye comprises the application, resorption, bioavailability, metabolization and elimination of topically administered drugs. In addition to the necessity of the penetration of the substance through the naturally occurring barriers of the eye in the form of the tear film, cornea, conjunctiva and sclera, the correct technique for administration is necessary for an optimal effect of the drug. Several new application devices have been described in the literature but most are still in an experimental phase. The main aims are to increase drug exposure time to the anterior surface of the eye and decrease problems in administration. Furthermore, new preservative agents are in use in order to produce less toxic side effects.

摘要

眼前段的药代动力学包括局部给药药物的应用、吸收、生物利用度、代谢和消除。除了药物必须以泪膜、角膜、结膜和巩膜的形式穿透眼睛的天然屏障外,正确的给药技术对于药物的最佳效果也是必要的。文献中描述了几种新的给药装置,但大多数仍处于实验阶段。主要目的是增加药物在眼前表面的暴露时间并减少给药问题。此外,正在使用新的防腐剂以产生毒性较小的副作用。

相似文献

1
[Pharmacokinetics of the anterior eye].[眼前部的药代动力学]
Ophthalmologe. 2014 Feb;111(2):107-12. doi: 10.1007/s00347-013-2931-x.
2
[Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].[眼药代动力学:局部、玻璃体内及全身用药]
Ophthalmologe. 2014 Feb;111(2):104-6. doi: 10.1007/s00347-013-2930-y.
3
Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.纳米技术在眼前段局部给药中的应用。
Int J Mol Sci. 2021 Nov 16;22(22):12368. doi: 10.3390/ijms222212368.
4
[Pharmacokinetics of intravitreally administered VEGF inhibitors].玻璃体内注射血管内皮生长因子抑制剂的药代动力学
Ophthalmologe. 2014 Feb;111(2):113-20. doi: 10.1007/s00347-013-2932-9.
5
Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.眼用制剂和接触镜经眼部给药到前房的机制模型研究。
Adv Colloid Interface Sci. 2016 Jul;233:139-154. doi: 10.1016/j.cis.2015.08.002. Epub 2015 Aug 14.
6
Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.局部抗TNF-α单链抗体(ESBA105)在无渗透促进剂的情况下对眼内前后节的高效穿透。
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):779-86. doi: 10.1167/iovs.08-2372. Epub 2008 Aug 29.
7
A compartment model to calculate time-dependent concentration profiles of topically applied chemical compounds in the anterior compartments of the rabbit eye.
Altern Lab Anim. 2001 May-Jun;29(3):347-65. doi: 10.1177/026119290102900318.
8
Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.胶束:用于前节和后节疾病的有前途的眼部药物载体。
J Ocul Pharmacol Ther. 2020 Jul/Aug;36(6):323-341. doi: 10.1089/jop.2019.0109. Epub 2020 Apr 20.
9
Nanoparticles for drug delivery to the anterior segment of the eye.用于眼部前段递药的纳米粒。
Adv Drug Deliv Rev. 2017 Dec 1;122:31-64. doi: 10.1016/j.addr.2017.04.001. Epub 2017 Apr 6.
10
Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes.测定眼科药物通过猪、兔和牛眼不同层的渗透系数。
Eur J Pharm Sci. 2012 Aug 30;47(1):131-8. doi: 10.1016/j.ejps.2012.05.007. Epub 2012 May 30.

本文引用的文献

1
Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial.0.03% 无防腐剂贝美前列素滴眼液对比 0.03% 贝美前列素滴眼液(卢美根)治疗青光眼或高眼压症:一项为期 12 周、随机、双盲的试验。
Br J Ophthalmol. 2013 Aug;97(8):989-93. doi: 10.1136/bjophthalmol-2012-303040. Epub 2013 Jun 6.
2
Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.抗青光眼前列腺素(PG)类似物眼用制剂中添加剂的安全性比较
Clin Ophthalmol. 2013;7:515-20. doi: 10.2147/OPTH.S40147. Epub 2013 Mar 12.
3
Dexamethasone eye drops containing γ-cyclodextrin-based nanogels.
含 γ-环糊精纳米凝胶的地塞米松滴眼液。
Int J Pharm. 2013 Jan 30;441(1-2):507-15. doi: 10.1016/j.ijpharm.2012.11.002. Epub 2012 Nov 10.
4
Time course of changes in ocular wavefront aberration after administration of eye ointment.眼药膏给药后眼波前像差变化的时间过程。
Eye (Lond). 2012 Oct;26(10):1310-7. doi: 10.1038/eye.2012.142. Epub 2012 Jul 20.
5
Evaluation of cytotoxic potential of cored soft contact lenses with adsorbed active ingredients from over-the-counter eye drops.
J Toxicol Sci. 2012;37(3):639-43. doi: 10.2131/jts.37.639.
6
The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops.人工泪液评价中的体外眼刺激性试验(EVEIT):保存用与未保存的滴眼液。
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1333-40. doi: 10.1007/s00417-012-1999-3. Epub 2012 May 15.
7
Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial.眼睑闭合对前列腺素类药物降低眼压效果的影响:一项随机对照试验。
Br J Ophthalmol. 2012 Feb;96(2):250-3. doi: 10.1136/bjo.2010.198887. Epub 2011 Apr 21.
8
Recent perspectives in ocular drug delivery.眼部给药的最新观点。
Pharm Res. 2009 May;26(5):1197-216. doi: 10.1007/s11095-008-9694-0. Epub 2008 Aug 29.
9
Formulation and evaluation of ciprofloxacin hydrochloride soluble ocular drug insert.盐酸环丙沙星可溶性眼用药物插入剂的制剂与评价
Curr Eye Res. 2008 May;33(5):469-75. doi: 10.1080/02713680802023104.
10
Nanotechnology in ocular drug delivery.眼部药物递送中的纳米技术。
Drug Discov Today. 2008 Feb;13(3-4):144-51. doi: 10.1016/j.drudis.2007.10.021.